Sees FY26 Adjusted EBITDA of $480 Million to $505 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy OPCH?
Sees FY26 adjusted EBITDA of $480 million to $505 million
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPCH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPCH
Wall Street analysts forecast OPCH stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.600
Low
27.00
Averages
36.22
High
40.00
Current: 31.600
Low
27.00
Averages
36.22
High
40.00
About OPCH
Option Care Health, Inc. is an independent provider of home and alternate site infusion services. The Company’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women’s health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 Index rose by 0.77%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 Index climbed by 1.09%, indicating a recovery after Monday's sharp declines, reflecting investor optimism regarding economic data.
- Software and Chip Stocks Surge: Following AI startup Anthropic PBC's emphasis on partnerships, software and chip manufacturers saw significant stock price increases, indicating growing market confidence in the integration of AI technologies, which could enhance their competitive positioning.
- Consumer Confidence Boost: The US February consumer confidence index rose by 2.2 to 91.2, surpassing expectations of 87.1, suggesting increased consumer optimism about the economic outlook, which may lead to higher consumer spending and positively impact economic growth.
- Interest Rates and Economic Data Focus: The market is discounting only a 2% chance of a rate cut at the Fed's March 17-18 meeting, indicating cautious investor sentiment regarding future monetary policy, while closely monitoring upcoming corporate earnings and economic data releases.
See More
Option Care Health Q4 2025 Earnings Call Insights
- Patient Service Growth: In 2025, Option Care Health served over 315,000 unique patients and completed more than 2.5 million infusion events, solidifying its position as the largest independent provider of home and alternate site infusion therapy in the U.S., showcasing the company's strong competitive edge in the market.
- Revenue and Profit Increase: The company reported net revenue of $5.6 billion for 2025, a 13% increase year-over-year, with adjusted EBITDA of $471 million, up 6%, indicating balanced growth across acute and chronic therapies and reflecting the effectiveness of its business model.
- Technology Investment and Efficiency: Investment in artificial intelligence has enabled approximately 40% of claims to be processed without human intervention, enhancing operational efficiency, while the opening of over 25 ambulatory infusion clinics led to a more than 25% increase in infusion clinic visits in Q4, further strengthening customer service capabilities.
- Future Outlook and Challenges: Management expects 2026 revenue to range between $5.8 billion and $6 billion, despite facing a 400 basis point revenue headwind from Stelara biosimilars, the company remains optimistic about future growth, emphasizing continued expansion of payer partnerships and technology investments to navigate market changes.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 index rose by 0.50%, the Dow Jones Industrial Average by 0.75%, and the Nasdaq 100 by 0.90%, indicating a gradual recovery after Monday's sharp declines, reflecting renewed investor confidence in economic prospects.
- Consumer Confidence Boost: The February consumer confidence index in the US increased by 2.2 to 91.2, surpassing expectations of 87.1, suggesting that rising consumer optimism could drive spending and positively impact economic growth.
- Strong Software Stock Recovery: Thomson Reuters shares surged by 12% after reaching one million professional users of its AI tool, indicating high market acceptance and potential for further revenue growth, enhancing its competitive position.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 basis point rate cut at the Fed's March meeting, reflecting cautious investor sentiment regarding future monetary policy, which may influence short-term stock market volatility.
See More
US Stocks Rebound Slightly as Software Shares Recover
- Market Rebound: The S&P 500 index rose by 0.17%, the Dow Jones Industrial Average increased by 0.64%, and the Nasdaq 100 index climbed by 0.47%, indicating a recovery after Monday's sharp declines, reflecting renewed investor confidence in software companies.
- Trade Uncertainty: President Trump's new 10% global tariffs took effect today, and concerns about a potential increase to 15% amid Supreme Court rulings may negatively impact the stock market, particularly with rising geopolitical risks.
- Home Price Index Growth: The US December S&P Composite-20 home price index rose 0.47% month-over-month and 1.38% year-over-year, surpassing expectations, suggesting resilience in the housing market that could support economic recovery and influence investor sentiment.
- Corporate Earnings Optimism: Over 80% of S&P 500 companies have reported earnings, with 74% exceeding expectations, and Q4 earnings growth is projected at 8.4%, indicating strong corporate performance that may drive further stock market gains.
See More
Option Care Health Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: Option Care Health reported a Q4 non-GAAP EPS of $0.46, missing expectations by $0.01, while revenue reached $1.47 billion, an 8.9% year-over-year increase, exceeding market expectations by $10 million, indicating strong revenue growth.
- Adjusted EBITDA Growth: The company achieved an adjusted EBITDA of $126 million, up 3.7% year-over-year, demonstrating its efforts to enhance operational efficiency and profitability despite facing challenges.
- 2026 Financial Guidance: Option Care Health projects net revenue for 2026 to be between $5.8 billion and $6.0 billion, slightly below the consensus of $5.98 billion, with adjusted diluted EPS expected to be between $1.82 and $1.92, reflecting a cautiously optimistic outlook for the future.
- Cash Flow Performance: The company anticipates cash provided by operating activities to be at least $340 million, which will support ongoing investments and business transformation, even though the transformation process may encounter certain difficulties.
See More
Option Care Health Set to Announce Q4 Earnings with Strong Estimates
- Earnings Announcement Date: Option Care Health (OPCH) is set to announce its Q4 earnings on February 24 before market open, with a consensus EPS estimate of $0.47, reflecting a 6.8% year-over-year growth, indicating sustained profitability.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $1.46 billion, representing an 8.4% year-over-year increase, which underscores the company's robust performance and rising customer demand, further solidifying its market position.
- Record of Beating Estimates: Over the past year, OPCH has beaten both EPS and revenue estimates 100% of the time, showcasing the company's accuracy in financial forecasting and execution, which enhances investor confidence.
- Upward Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, while revenue estimates have experienced five upward revisions, indicating analysts' optimistic outlook on the company's future performance, potentially driving stock price increases.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 Index rose by 0.77%, the Dow Jones Industrial Average increased by 0.76%, and the Nasdaq 100 Index climbed by 1.09%, indicating a recovery after Monday's sharp declines, reflecting investor optimism regarding economic data.
- Software and Chip Stocks Surge: Following AI startup Anthropic PBC's emphasis on partnerships, software and chip manufacturers saw significant stock price increases, indicating growing market confidence in the integration of AI technologies, which could enhance their competitive positioning.
- Consumer Confidence Boost: The US February consumer confidence index rose by 2.2 to 91.2, surpassing expectations of 87.1, suggesting increased consumer optimism about the economic outlook, which may lead to higher consumer spending and positively impact economic growth.
- Interest Rates and Economic Data Focus: The market is discounting only a 2% chance of a rate cut at the Fed's March 17-18 meeting, indicating cautious investor sentiment regarding future monetary policy, while closely monitoring upcoming corporate earnings and economic data releases.
See More
Option Care Health Q4 2025 Earnings Call Insights
- Patient Service Growth: In 2025, Option Care Health served over 315,000 unique patients and completed more than 2.5 million infusion events, solidifying its position as the largest independent provider of home and alternate site infusion therapy in the U.S., showcasing the company's strong competitive edge in the market.
- Revenue and Profit Increase: The company reported net revenue of $5.6 billion for 2025, a 13% increase year-over-year, with adjusted EBITDA of $471 million, up 6%, indicating balanced growth across acute and chronic therapies and reflecting the effectiveness of its business model.
- Technology Investment and Efficiency: Investment in artificial intelligence has enabled approximately 40% of claims to be processed without human intervention, enhancing operational efficiency, while the opening of over 25 ambulatory infusion clinics led to a more than 25% increase in infusion clinic visits in Q4, further strengthening customer service capabilities.
- Future Outlook and Challenges: Management expects 2026 revenue to range between $5.8 billion and $6 billion, despite facing a 400 basis point revenue headwind from Stelara biosimilars, the company remains optimistic about future growth, emphasizing continued expansion of payer partnerships and technology investments to navigate market changes.
See More
US Stocks Rebound Led by Software and Chipmakers
- Market Rebound: The S&P 500 index rose by 0.50%, the Dow Jones Industrial Average by 0.75%, and the Nasdaq 100 by 0.90%, indicating a gradual recovery after Monday's sharp declines, reflecting renewed investor confidence in economic prospects.
- Consumer Confidence Boost: The February consumer confidence index in the US increased by 2.2 to 91.2, surpassing expectations of 87.1, suggesting that rising consumer optimism could drive spending and positively impact economic growth.
- Strong Software Stock Recovery: Thomson Reuters shares surged by 12% after reaching one million professional users of its AI tool, indicating high market acceptance and potential for further revenue growth, enhancing its competitive position.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 basis point rate cut at the Fed's March meeting, reflecting cautious investor sentiment regarding future monetary policy, which may influence short-term stock market volatility.
See More
US Stocks Rebound Slightly as Software Shares Recover
- Market Rebound: The S&P 500 index rose by 0.17%, the Dow Jones Industrial Average increased by 0.64%, and the Nasdaq 100 index climbed by 0.47%, indicating a recovery after Monday's sharp declines, reflecting renewed investor confidence in software companies.
- Trade Uncertainty: President Trump's new 10% global tariffs took effect today, and concerns about a potential increase to 15% amid Supreme Court rulings may negatively impact the stock market, particularly with rising geopolitical risks.
- Home Price Index Growth: The US December S&P Composite-20 home price index rose 0.47% month-over-month and 1.38% year-over-year, surpassing expectations, suggesting resilience in the housing market that could support economic recovery and influence investor sentiment.
- Corporate Earnings Optimism: Over 80% of S&P 500 companies have reported earnings, with 74% exceeding expectations, and Q4 earnings growth is projected at 8.4%, indicating strong corporate performance that may drive further stock market gains.
See More
Option Care Health Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: Option Care Health reported a Q4 non-GAAP EPS of $0.46, missing expectations by $0.01, while revenue reached $1.47 billion, an 8.9% year-over-year increase, exceeding market expectations by $10 million, indicating strong revenue growth.
- Adjusted EBITDA Growth: The company achieved an adjusted EBITDA of $126 million, up 3.7% year-over-year, demonstrating its efforts to enhance operational efficiency and profitability despite facing challenges.
- 2026 Financial Guidance: Option Care Health projects net revenue for 2026 to be between $5.8 billion and $6.0 billion, slightly below the consensus of $5.98 billion, with adjusted diluted EPS expected to be between $1.82 and $1.92, reflecting a cautiously optimistic outlook for the future.
- Cash Flow Performance: The company anticipates cash provided by operating activities to be at least $340 million, which will support ongoing investments and business transformation, even though the transformation process may encounter certain difficulties.
See More
Option Care Health Set to Announce Q4 Earnings with Strong Estimates
- Earnings Announcement Date: Option Care Health (OPCH) is set to announce its Q4 earnings on February 24 before market open, with a consensus EPS estimate of $0.47, reflecting a 6.8% year-over-year growth, indicating sustained profitability.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $1.46 billion, representing an 8.4% year-over-year increase, which underscores the company's robust performance and rising customer demand, further solidifying its market position.
- Record of Beating Estimates: Over the past year, OPCH has beaten both EPS and revenue estimates 100% of the time, showcasing the company's accuracy in financial forecasting and execution, which enhances investor confidence.
- Upward Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, while revenue estimates have experienced five upward revisions, indicating analysts' optimistic outlook on the company's future performance, potentially driving stock price increases.
See More
